Relato de um caso de transplante de células mesenquimais do cordão umbilical em paciente com distrofia de Emery-Dreifus

China - o autor relata uma caso de distrofia de Emery-Dreifus internado por infarto cerebelar e que foi tratado com células tronco mesenquimais retiradas do cordão umbilical e compatíveis imunologicamente. Houve melhora das condições clínicas e redução dos níveis de CK após o tratamento.

As informações são limitadas e o resumo em inglês e pode ser lido abaixo:

(Journal of Clinical Rehabilitation Tissue Engineering Research. 13(27):5393-5396, July 2, 2009) Allogeneic cord blood mesenchymal stem cell transplantation for treating Emery-Dreifus muscular dystrophy in one case. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2009;13(27): 5393-5396(China)
Liao Y. - China

A male patient, aged 32 years, weighing 38 kg, was recruited at the Department of Neurology, Wuxi Second Hospital, Nanjing Medical University in February 2008. The patient had general fatigue and amyotrophy for 18 years, and recruited in the hospital 3 days following burst dizziness and vomiting. Following genetic analysis and muscle biopsy, the patient was diagnosed as having Emery-Dreifus muscular dystrophy and cerebellar infarction. HLA compatible cord blood mesenchymal stem cell (CB-MSC) transplantation was performed. The grafted CB-MSCs were from Shanghai Cord Blood Bank. The donor was HIA all-identical, Rh blood type-identical, ABO blood type-incompatible. The patient received preconditioning of busulfan + cyclophosphamide + rabbit antithymocyte globulin. The patient then received peripheral venous administration of 40 mL CB-MSCs, 10 drops/minute, with total nucleated cell number of 31.98x108. 5 weeks after transplantation, symptoms of dizziness, swallowing difficulty and regurgitation of fluid were markedly alleviated. His weight increased by 4 kg and he recovered of hand coordination to handling computer operation. 6 months following transplantation, serum creatine phosphokinase decreased from 35.79 [mu]kat/L before transplantation to 9.55 [mu]kat/L; serum creatine phosphokinase isoenzyme reduced from 18.20 [mu]kat/L before transplantation to 4.78 [mu]kat/L. Myoglobin decreased from 413.50 [mu]g/L to 213.20 [mu]g/L. Functional independence measure scores increased from 71 points to 101 points. Immunological rejection or tumorigenesis was not identified. CB-MSC transplantation can evidently decrease serum creatine phosphokinase level within a short period, and improve motor function in Emery-Dreifus muscular dystrophy patient. CB-MSC transplantation is beneficial for Emery-Dreifus muscular dystrophy, and short-term safety is reliable.

Fonte: http://distrofiamuscular.net/noticias.htm